Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

r the Agreement with Janssen of $50 million each, totaling $200 million, including the $50 million milestone earned on April 11, 2013, which the Company expects to collect during the quarter ended June 30, 2013. The Company may earn up to an additional $625 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general, Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. As of March 31, 2013, the Company's total share of collaboration costs for the 2013 calendar year to date was approximately $24.9 million.

"This past quarter has been particularly successful for our company," said Bob Duggan, CEO and Chairman of the Board. "We completed the enrollment of our first Phase III trial and are well on track with our clinical programs. We also received the third Breakthrough Therapy Designation from the FDA. Last month at the American Association of Clinical Research we had 8 poster presentations and 1 oral presentation. There are 5 additional oral and 6 poster presentations with clinical and pre-clinical updates planned for the upcoming scientific conferences this summer, the American Society of Clinical Oncology, the European Hematology Association and the International Conference on Malignant Lymphoma. Last month we earned a milestone payment of $50 million from our collaboration partner Janssen, for the start of our front line study in CLL and on March 8th we concluded a successful equity offering netting us $201 million. Pharmacyclics remains resolute in it
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ ... provided a summary of clinical developments and announced ... Clinical Developments and Anticipated Near-term ... OncoGenex and Teva agreed to negotiate the termination ... OncoGenex. Negotiations of the final termination agreement are ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
(Date:3/27/2015)... 27, 2015 When struck with the ... to know where to begin. The latest eBook ... accident attorney, offers accident victims a clear and concise ... to ensure their personal injury claim is seen through ... the first actions that should be taken immediately following ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... Industry is a professional and in-depth study on ... market with a focus on the Chinese ... of the industry including definitions, classifications, applications and ... provided for both the international and Chinese domestic ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 April 2015 ... war – the Sesquicentennial. To honor America’s bloodiest war and ... Fort Adams Trust presents A Tribute to the Civil War ... PM, Friday, April 17, 2015, at the Jane Pickens Theater ... noted Civil War-Lincoln scholar, will serve as the master of ...
(Date:3/27/2015)... March 27, 2015 The ... Quaker-based, philanthropic, grant-making foundation committed to raising its ... healthcare is delivered. , The Scattergood Foundation and ... Behavioral Health Policy and Practice through the Annual ... Program App is designed to guide the ...
(Date:3/26/2015)... March 26, 2015 Alliance Healthcare Foundation ... and wellness for the poor and underserved in San ... for its annual $1 million award, the Innovation Initiative ... announce the 2015 round of our Innovation Initiative Award,” ... supported some incredibly creative and ambitious projects in the ...
Breaking Medicine News(10 mins):Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2
... Gerresheimer Stock in the SDAX as Per September 6, 2007 ... Outside the Normal Schedule, ... 5 September, DÜSSELDORF, Germany, September 3 Gerresheimer AG has,been listed ... following one of the largest IPOs of the year, with a total,issue ...
... we all know that tall parents are more likely to ... common genes that make people taller than others. Now, however, ... common variant of which directly influences height. , The ... the variant and a person carrying no copies is just ...
... 31, 2007) Two worldwide studies published in this week,s ... chronic obstructive pulmonary disease (COPD). The only U.S. site in ... in Eastern Kentucky, and was found to have some of ... fact, it had the second highest rate among women and ...
... designed for brain tumour therapy has shown promising tumour ... by scientists at The University of Nottingham. The project, ... and Human Development, will be featured in the September ... for brain cancers is particularly difficult for a number ...
... in on diacetyl, a key component of butter flavoring in ... key chemical ingredient in the buttery flavoring of microwave popcorn ... a lung disease that afflicts people who work in the ... Publishing in the September issue of the American Journal ...
... smoking are more likely to have sleep disturbances such ... sleep duration, and snoring loudly or breathing uncomfortably, according ... of the journal SLEEP. , The study, authored by ... focused on the responses of 16,396 and 19,386 pregnant ...
Cached Medicine News:Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 2Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 3Health News:Two studies published in the Lancet 2Health News:Novel 3-D cell culture model shows selective tumour uptake of nanoparticles 2Health News:Scientists ID Likely Culprit in 'Popcorn Lung' 2Health News:Passive smoking increases sleep disturbance among pregnant women 2
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds....
... enables hospitals to standardize ... to a single temperature ... monitoring disposale probes and ... in their manufacture and ...
... Level 1 enables ... multiparameter patient monitors to ... series. Our temperature monitoring ... cables are superior in ...
Medicine Products: